Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
We investigated the genotype-dependent therapeutic potential of targeting the phosphoinositide 3-kinase (PI3K)/Akt pathway for thyroid cancer. Proliferation of TPC1, Hth7, FTC133, OCUT1, K1, and BCPAP cells that harbored PI3K/Akt-activating genetic alterations was potently inhibited by the Akt inhibitor perifosine, whereas SW1736, Hth74, WRO, KAT18, and TAD2 cells that harbored no genetic alterations had no or only modest responses. Inhibition of Akt phosphorylation by perifosine was seen in these cells. Genetic-dependent apoptosis was induced by perifosine in cells selectively tested. Similarly, potent inhibition of cell proliferation by the mammalian target of rapamycin (mTOR) inhibitor temsirolimus occurred in virtually all the cells harboring genetic alterations, whereas modest inhibition was seen in some of the cells not harboring genetic alterations. Temsirolimus inhibited the phosphorylation of p70S6K, a substrate of mTOR. Knockdown of Akt1/2 or mTOR by shRNA approach inhibited the proliferation and colony formation of FTC133 and OCUT1 cells that harbored genetic alterations in the PI3K/Akt pathway but had no effect on SW1736 and KAT18 cells that did not. Transfection with PIK3CA mutants greatly sensitized SW1736 cells to perifosine and temsirolimus. Growth of xenograft tumors derived from FTC133 cells but not SW1736 cells in nude mice was dramatically inhibited by perifosine. Thus, this work for the first time shows that genetic alterations in the PI3K/Akt pathway confer thyroid cancer cells addiction to this pathway and their sensitivity to inhibition by targeting Akt and mTOR. This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies.
Liu
Dingxie
D
Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Hou
Peng
P
Liu
Zhi
Z
Wu
Guojun
G
Xing
Mingzhao
M
D000818:Animals; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D058534:Class I Phosphatidylinositol 3-Kinases; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D051058:Oncogene Protein v-akt / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011494:Protein Kinases / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
D058534:Class I Phosphatidylinositol 3-Kinases; D051058:Oncogene Protein v-akt; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010767:Phosphorylcholine; D011494:Protein Kinases; D034741:RNA, Small Interfering; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C105905:perifosine; C401859:temsirolimus; C546842:MTOR protein, human; C546843:mTOR protein, mouse; C484760:PIK3CA protein, human
J Clin Oncol. 2004 Jul 15;22(14):2954-63
15254063
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91
19240234
J Clin Endocrinol Metab. 2005 Aug;90(8):4688-93
15928251
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5
15240889
Clin Cancer Res. 2004 Nov 15;10(22):7450-6
15569974
Cell Signal. 2009 May;21(5):656-64
19166931
Immunol Cell Biol. 2000 Aug;78(4):447-51
10947872
BMC Cancer. 2009 Jan 27;9:34
19173737
Cancer Res. 2005 May 1;65(9):3664-70
15867361
Nat Med. 2008 Dec;14(12):1351-6
19029981
J Clin Endocrinol Metab. 2008 Feb;93(2):611-8
18000091
Cancer. 1998 Dec 15;83(12):2638-48
9874472
Cancer Treat Rev. 2004 Apr;30(2):193-204
15023437
J Clin Endocrinol Metab. 2008 Jan;93(1):278-84
17989125
JAMA. 2006 May 10;295(18):2164-7
16684987
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
16341064
Endocr Relat Cancer. 2009 Mar;16(1):17-44
18987168
Oncogene. 2008 Sep 18;27(41):5497-510
18794884
Cancer Res. 2005 Nov 15;65(22):10199-207
16288007
J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16
18492751
Endocr Pathol. 2008 Fall;19(3):150-5
18766471
J Clin Oncol. 2008 Oct 10;26(29):4708-13
18541897
Clin Cancer Res. 2007 Dec 15;13(24):7421-31
18094426
Clin Cancer Res. 2007 Feb 15;13(4):1161-70
17317825
Thyroid. 2004 Dec;14(12):1056-60
15650358
Endocrinology. 1997 Jun;138(6):2610-4
9165055
Curr Cancer Drug Targets. 2008 May;8(3):187-98
18473732
Cell Signal. 2002 May;14(5):381-95
11882383
Curr Opin Investig Drugs. 2002 Aug;3(8):1249-53
12211424
Mol Cell Biol. 1999 Jun;19(6):4525-34
10330191
Clin J Oncol Nurs. 2008 Aug;12(4):639-46
18676330
Herz. 1999 May;24(3):189-95
10412642
Hum Mol Genet. 2001 Feb 1;10(3):251-8
11159944
PLoS One. 2008 Aug 26;3(8):e3065
18725974
J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41
18713817
Curr Pharm Des. 2008;14(21):2061-74
18691116
Eur J Cancer. 2002 Aug;38(12):1615-21
12142051
Endocrinol Metab Clin North Am. 2008 Jun;37(2):525-38, xi
18502341
N Engl J Med. 2008 Jul 3;359(1):31-42
18596272
Cancer Res. 2002 Sep 1;62(17):5027-34
12208757
Breast Cancer Res Treat. 2008 Nov;112(2):217-27
18074223
Methods Enzymol. 1994;235:29-39
8057901
Curr Oncol Rep. 2009 Mar;11(2):102-10
19216841
J Clin Oncol. 2008 Oct 10;26(29):4714-9
18541894
Cancer Res. 2001 Aug 15;61(16):6105-11
11507060
J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90
17426084
Otolaryngol Clin North Am. 2008 Dec;41(6):1135-46, ix
19040974